Table 1. Summary of treatment modalities in low-grade glioma categorized according to the studied variables.
| Treatment modality | Variable | References | ||
|---|---|---|---|---|
| Surgery | EOR | 5-year OS rate* | 39,27 | |
| ≥90% | 91–97% | |||
| <90% | 60–76% | |||
| Radiotherapy | Risk level | Management | 31 | |
| Low | IDHmut | ‘Wait and see’ | ||
| IDHwt | Radiochemotherapy | |||
| High | - | Radiochemotherapy | ||
| Dose | 5-year OS rate | |||
| 45 vs. 59.4 Gy | 58% vs. 59% | 20 | ||
| 50.4 vs. 64.8 Gy | 72% vs. 64% | 36 | ||
| Timing | PFS* | OS | ||
| Early vs. late (median time) | 5.3 vs. 3.4 years | 7.4 vs. 7.2 years | 3 | |
| Early vs. late (5-year rate) | 44% vs. 37% | 63% vs. 66% | 21 | |
| Chemotherapy | Regimen | OS* | ||
| PCV+radiotherapy vs. radiotherapy | 13.3 vs. 7.8 years | 7 | ||
| TMZ+radiotherapy vs. radiotherapy | 65% vs. 54% (3-year rate) | 17 | ||
| Postoperative TMZ alone | 82% (3-year rate) | 5 | ||
| 4-year PFS† | ||||
| TMZ vs. radiotherapy | Overall | 3.3% vs. 3.8% | 1 | |
| Molecular subtype | ||||
| IDH mutant without codeletion | 36 vs. 55 months | |||
| IDH mutant with codeletion | n.s. | |||
| IDH wild-type | n.s. | |||
*Statistically significant, †OS could not be determined.
EOR: extent of resection, n.s.: not significant, OS: overall survival, PCV: procarbazine, lomustine, and vincristine, PFS: progression-free survival, TMZ: temozolomide.